Cargando…
An Algorithm for the Preclinical Screening of Anticancer Drugs Effective against Brain Tumors
The anticancer drugs screening program is a long and expensive process. It is estimated that only 5% of drugs entering clinical trials are approved by the FDA. Moreover, many of the drugs that enter clinical trials are often of limited use in clinical practice, and most cancers remain untreatable. B...
Autor principal: | Yakisich, Juan Sebastian |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
International Scholarly Research Network
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3398605/ https://www.ncbi.nlm.nih.gov/pubmed/22830045 http://dx.doi.org/10.5402/2012/513580 |
Ejemplares similares
-
Ionophores: Potential Use as Anticancer Drugs and Chemosensitizers
por: Kaushik, Vivek, et al.
Publicado: (2018) -
Anticancer Drug Development: Preclinical Screening, Clinical Trials and Approval
por: Selwood, D
Publicado: (2004) -
Anticancer drug development: preclinical screening, clinical trials and approval
por: Teicher, B A, et al.
Publicado: (2004) -
Human Tumor Xenograft Models for Preclinical Assessment of Anticancer Drug Development
por: Jung, Joohee
Publicado: (2014) -
Cannabinoids as anticancer drugs: current status of preclinical research
por: Hinz, Burkhard, et al.
Publicado: (2022)